In ERA 2024's best-ranked abstract, we presented 72-week eGFR stabilization from our Phase 2b clinical trial for #IgANephropathy. We also showed rapid hematuria improvement and significantly higher hematuria resolution compared to placebo during the 36-week randomized period. Read the press release here: https://lnkd.in/eRcDMqd5 #ERA24
Vera Therapeutics, Inc.’s Post
More Relevant Posts
-
Last month in April 2024, Arvinas entered into a transaction with Novartis, including a Global License Agreement for the Development and Commercialization of ARV-766 for the treatment of Prostate Cancer. Findings during the ASCO 2024 conference revealed that ARV-766, an investigational PROTAC androgen receptor degrader, exhibited encouraging clinical activity alongside manageable toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). In a Phase I/II study involving pretreated mCRPC patients, ARV-766 demonstrated favorable tolerability and promising clinical efficacy, particularly in individuals with tumors harboring AR LBD mutations. These results underscore the potential of ARV-766 as a valuable addition to the armamentarium for advanced prostate cancer, warranting further development and investigation. Discover Expert Insights and In-Depth Analysis with DelveInsight's Exclusive ASCO 2024 Coverage @ https://lnkd.in/ggacy4En #asco #asco24 #asco2024 #ascoconference #Arvinas #Novartis #GlobalLicenseAgreement #ARV766 #ProstateCancerTreatment #PROTAC #AndrogenReceptorDegrader #ClinicalActivity #ManageableToxicity #mCRPC #PhaseI_IIStudy #TumorResponse #ARLBDMutations #AdvancedProstateCancer #ClinicalEfficacy #DrugDevelopment #CancerResearch #OncologyInnovation #PersonalizedMedicine #HealthcareAdvances #ScienceNews #MedicalBreakthrough #Pharmaceuticals
To view or add a comment, sign in
-
Human Clinical Article: This phase IIA clinical trial reports the safety and therapeutic efficacy of autologous chondroprogenitor cells derived from the nasal septum for the treatment of patients with temporomandibular joint. https://lnkd.in/d6mUJAxq
To view or add a comment, sign in
-
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
Matching top talent to meaningful careers at Parexel #withheart 💜 Recruiting positions for US, Canada and EMEA
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in
-
As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more:
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
share.parexel.social
To view or add a comment, sign in